Ophthalmologists are not spared from the opioid epidemic. Recent studies have shown that opioids continue to be prescribed after ophthalmic surgeries. Dr. Drew Carey interviews Dr. Matthew R. Starr on his retrospective study published in Ophthalmology, “Hospitalization, Overdose, and Mortality After Opioid Prescriptions Tied to Ophthalmic Surgery.”

Hospitalization, Overdose, and Mortality After Opioid Prescriptions Tied to Ophthalmic Surgery. Thao, Viengneesee et al. Ophthalmology, Volume 131, Issue 8, 943 – 949.

Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

The RID-MyC assay, a CRISPR/Cas12a-based test, offers swift and reliable detection of Fungal Keratitis, enhancing diagnostic capabilities at point-of-care settings. Dr. Rajesh Rao interviews Dr. Siddharth Narendran on the development of this assay from his Ophthalmology Science article, “Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses.”

Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses. Deivarajan, Hanith Raj et al. Ophthalmology Science, Volume 4, Issue 5.

Join Ophthalmology’s Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor’s Choice Highlights From the Ophthalmology Journal Family” in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

Dr. Matt Feng is joined by Dr. Thomas H. Dohlman to discuss the effectiveness of topical and subconjunctival bevacizumab in suppressing vascularization in graft and host bed after high-risk corneal transplantation, from his Ophthalmology Science article “Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation”

Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation. Dohlman, Thomas H. et al. Ophthalmology Science, Volume 4, Issue 4.